![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NEUROPHARMACOLOGY
International Centre for Neurotherapeutics, Dublin City University, Dublin, Ireland (G.L., J.W., J.O.D); Hematology Department, Imperial College, London, United Kingdom (C.K.N.K.C); and Biological Sciences, Allergan LLC, Irvine, California (K.R.A)
The unique ability of a family of botulinum neurotoxins to block neuroexocytosis specificallyby selective interaction with peripheral cholinergic nerve endings, endocytotic uptake, translocation to the cytosol, and enzymic cleavage of essential proteinsunderlies their increasing therapeutic applications. Although clinical use of type A is most widespread due to its prolonged inactivation of the synaptosomal-associated protein of 25 kDa, botulinum neurotoxin E cleaves this same target but at a different bond and exhibits faster onset of neuromuscular paralysis. Herein, insights were gained into the different dynamics of action of types A and E toxins, which could help in designing variants with new pharmacological profiles. Natural and recombinant type E dichain forms showed similar proteolytic and neuromuscular paralytic activities. The neuroparalysis induced by type E toxin was accelerated between 21 and 35°C and attenuated by bafilomycin A1. Temperature elevation also revealed an unanticipated bipartite dose response indicative of two distinct internalization processes, one being independent of temperature and the other dependent. Although elevating the temperature also hastened intoxication by type A, a second uptake mechanism was not evident. Increasing the frequency of nerve stimulation raised the uptake of type E via both processes, but the enhanced trafficking through the temperature-dependent pathway was only seen at 35°C. These novel observations reveal that two membrane retrieval mechanisms are operative at motor nerve terminals which type E toxin exploits to gain entry via an acidification-dependent step, whereas A uses only one.
Address correspondence to: Dr. J. Oliver Dolly, International Centre for Neurotherapeutics, Dublin City University, Dublin 9, Ireland. E-mail: oliver.dolly{at}dcu.ie
This article has been cited by other articles:
![]() |
J. Wang, J. Meng, G. W. Lawrence, T. H. Zurawski, A. Sasse, M. O. Bodeker, M. A. Gilmore, E. Fernandez-Salas, J. Francis, L. E. Steward, et al. Novel Chimeras of Botulinum Neurotoxins A and E Unveil Contributions from the Binding, Translocation, and Protease Domains to Their Functional Characteristics J. Biol. Chem., June 20, 2008; 283(25): 16993 - 17002. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Chen and J. T. Barbieri Multiple Pocket Recognition of SNAP25 by Botulinum Neurotoxin Serotype E J. Biol. Chem., August 31, 2007; 282(35): 25540 - 25547. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Fischer and M. Montal Single molecule detection of intermediates during botulinum neurotoxin translocation across membranes PNAS, June 19, 2007; 104(25): 10447 - 10452. [Abstract] [Full Text] [PDF] |
||||